The effect of midlife cardiovascular risk factors on white matter hyperintensity volume and cognition two decades later in normal ageing women

R Aljondi; C Szoeke; C Steward; A Gorelik; P Desmond

Journal article

The effect of midlife cardiovascular risk factors on white matter hyperintensity volume and cognition two decades later in normal ageing women

R Aljondi, C Szoeke, C Steward, A Gorelik, P Desmond

Brain Imaging and Behavior | SPRINGER | Published : 2020

DOI: 10.1007/s11682-018-9970-5

Abstract

Cerebral White Matter Hyperintensity (WMH) lesions have been identified as markers of cerebrovascular diseases and they are associated with increased risk of cognitive impairment. In this study, we investigated the relationship between midlife cardiovascular risk factors and late life WMH volumes two decades later, and examined their association with cognitive performance. 135 participants from the Women’s Healthy Ageing Project had completed midlife cardiovascular risk measurement in 1992 and late life brain MRI scan and cognitive assessment in 2012. In these community-dwelling normal aging women, we found that higher midlife Framingham Cardiovascular Risk Profile (FCRP) score was associate..

View full abstract

University of Melbourne Researchers

Cassandra Szoeke Author

Chris Steward Author

Alex Gorelik Author

Patricia Desmond Author

Related Projects (2)

MODIFIABLE RISK FACTORS FOR COGNITIVE IMPAIRMENT IN AGEING

This study focuses on age-related decline in cognitive function in midlife.Early detection of people at risk will allow the introduction of ..

WOMEN'S HEALTHY AGEING COGNITIVE PROJECT

The changes of Alzheimer’s disease occur a decade prior to symptoms. Therefore we need longitudinal prospective data over 20 years to determ..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study is funded by the National Health and Medical Research Council (NHMRC Grants 547500, 1032350 & 1062133), Ramaciotti Foundation, Australian Healthy Ageing Organisation, the Brain Foundation, the Alzheimer's Association (NIA320312), Australian Menopausal Society, Bayer Healthcare, Shepherd Foundation, Scobie and Claire Mackinnon Foundation, Collier Trust Fund, J. O. & J.R. Wicking Trust, Mason Foundation and the Alzheimer's Association of Australia. Inaugural funding was provided by VicHealth and the NHMRC. The Principal Investigator of WHAP (CSz) is supported by the National Health and Medical Research Council.